White Paper: Utility and Application of the VeriKine Human IFN-α Multi-Subtype Serum ELISA

Content:

  • Systemic lupus erythematosus (SLE) and IFN-α
  • Virology and IFN-α
  • IFN-α and Pharmacodynamics (PD)
  • IFN-α as a marker of toxicology
  • Benefits of the VeriKine Human IFN-α Multi-subtype Serum ELISA Kit

Abstract

Generation of type I interferons (IFNs) occurs downstream of a multitude of immunologic stimuli. The production of these cytokines can be either a positive prognostic, as in defensive immunity against a pathogenic insult, or a negative prognostic, as in promotion of autoimmunity. In humans, the designation “IFN−α” is used to represent a family of proteins comprised of at least 12 highly homologous protein subtypes that exhibit diverse biologic activities. IFN−α can be used as a therapeutic agent in disease treatment regimens, as a downstream readout of the effectiveness of several drug therapies currently in the pipeline, and as a marker of pathology in human clinical and preclinical studies. The necessity of having a simple, cost-effective, and highly reproducible assay for detecting IFN−α is unquestionable. However, the requirements of such an assay are complicated by the need to simultaneously detect not just one, but numerous subtypes of IFN−α proteins. Of the various medium- to high-throughput assays available that may be useful in such efforts, the VeriKine Human Interferon Alpha Serum enzyme linked immuno-sorbent assay (ELISA) stands out for its ease of use, sensitivity, reproducibility, and ability to simultaneously detect multiple IFN−α subtypes. The application of this assay to a variety of R&D and clinical trial settings is described below, followed by an overview of the unique methodological benefits of this assay.

 

(Click here to download)

Find your product of interest by searching for category, species, molecule and/or application.

Visit our blog to read about recent developments in the fields of interferon, cytokine and biomarker research!

Sign up for our mailing list to be kept up-to-date on the latest promotions, company and product news.

Go to top